Abstract
Whilst fragment-based screening has found significant utility in aiding the discovery of high quality hits against a range of targets, the use of this technology in the protein-protein interaction inhibitor field is very much in its infancy. This review aims to highlight the key technologies used to identify fragment hits, such as NMR, SPR, X-ray crystallography and biochemical screening, the fragmentbased protein-protein interaction case studies reported to date and, more importantly, the potential of this methodology in unearthing high quality hit molecules in this critical area of drug discovery. In addition, we also discuss some of the key aspects of fragment library design, the composition of a high quality library and suggest ways in which future, more structurally diverse fragments which occupy different regions of chemical space to the vast majority of current fragment libraries may be selected.
Keywords: Fragment-based drug discovery, protein-protein interactions, hot spots, ligand efficiency, biophysical, techniques, inhibitors, fragment libraries, diversity, NMR.
Current Pharmaceutical Design
Title:Using Fragment-Based Technologies to Target Protein-Protein Interactions
Volume: 18 Issue: 30
Author(s): Justin F. Bower and Andrew Pannifer
Affiliation:
Keywords: Fragment-based drug discovery, protein-protein interactions, hot spots, ligand efficiency, biophysical, techniques, inhibitors, fragment libraries, diversity, NMR.
Abstract: Whilst fragment-based screening has found significant utility in aiding the discovery of high quality hits against a range of targets, the use of this technology in the protein-protein interaction inhibitor field is very much in its infancy. This review aims to highlight the key technologies used to identify fragment hits, such as NMR, SPR, X-ray crystallography and biochemical screening, the fragmentbased protein-protein interaction case studies reported to date and, more importantly, the potential of this methodology in unearthing high quality hit molecules in this critical area of drug discovery. In addition, we also discuss some of the key aspects of fragment library design, the composition of a high quality library and suggest ways in which future, more structurally diverse fragments which occupy different regions of chemical space to the vast majority of current fragment libraries may be selected.
Export Options
About this article
Cite this article as:
F. Bower Justin and Pannifer Andrew, Using Fragment-Based Technologies to Target Protein-Protein Interactions, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651689
DOI https://dx.doi.org/10.2174/138161212802651689 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design Promiscuous Binding Nature of Sh3 Domains to their Target Proteins
Protein & Peptide Letters Essential Role of Gli Proteins in Glioblastoma Multiforme
Current Protein & Peptide Science Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Current Medicinal Chemistry Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Current Topics in Medicinal Chemistry Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
Current Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets VFP: A Visual Algorithm for Predicting Gene Fusion in RNA-Seq Data
Current Bioinformatics Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets An MDR-EGFP Gene Fusion Allows for Direct Cellular Localization, Function and Stability Assessment of P-Glycoprotein
Current Drug Delivery Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Transposons for Gene Therapy!
Current Gene Therapy Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Production of Retroviral Vectors: Review
Current Gene Therapy